Sacituzumab govitecan for metastatic urothelial carcinoma progressing after chemotherapy and ICIs

Sacituzumab govitecan (SG) is a TROP-2-directed antibody drug conjugate with a SN-38 payload. The multinational phase 2 study TROPHY-U-01 evaluated SG for metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. The ORR was 27% (95% CI 19.5-36.6) while 77% of patients had decrease in measurable disease. Median duration of response was 7.2 months (95% CI 4.7-8.6), median PFS was 5.4 months (3.5-7.2) and median OS was 10.9 months (9.0-13.8). Rate of discontinuation due to TRAEs was 6%.